Aleksandar Topličanin

Dr. Aleksandar Topličanin

University Clinical Center, Serbia, Belgrade, Belgrade, Beograd, Serbia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2022 in Medicina
Verified
Journal Article
Open access
PDF file
TGTijana Glisic
Tijana Glisic
MLMilica Stojkovic Lalosevic
Milica Stojkovic Lalosevic
TMTamara Milovanovic
Tamara Milovanovic
Ivan RankovićIvan Ranković
Ivan Ranković
MSMarija Stojanovic
Marija Stojanovic
DPDusan Dj Popovic
Dusan Dj Popovic
Background and Objectives: Upper endoscopy is considered the gold standard for screening and diagnosis of esophageal varices (EV). Non-invasive methods for predicting EV have become a research hotspot in recent years. The aim of this study was to assess the role of non-invasive scores in predicting the presence of EV in patients with liver cirrhosis, and to determine the value of these scores in predicting the outcome of patients with cirrhosis presenting with acute variceal bleeding. Materials and Methods: A total of 386 patients with liver cirrhosis were included. The model for end-stage liver disease (MELD), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AST/ALT), AST to platelet ratio index (APRI), fibrosis-4-index (FIB-4), fibrosis index (FI), King’s Score, albumin-bilirubin (ALBI) score, and platelet-albumin-bilirubin (PALBI) score were calculated. The discriminatory capacities of the examined scores in predicting the presence of esophageal varices were tested using receiver operating characteristic (ROC) curves. Results: The ROC curve analysis showed (area under the curve) AUC values of ALBI and PALBI of 0.603, and 0.606, respectively, for the prediction of EV. APRI, MELD, PALBI, King’s, FIB-4, and ALBI scores showed statistically significant correlation with EV bleeding (p < 0.05). AUC of APRI and MELD for predicting EV bleeding were 0.662 and 0.637, respectively. The AUC value of MELD in short-term mortality was 0.761. Conclusions: ALBI and PALBI scores had modest diagnostic accuracy of EVs in liver cirrhosis. APRI and MELD can be used as a reference index for the EV bleeding, and MELD score is best associated with short-term outcome in cirrhotic patients.

Verified
Journal Article
Open access
PDF file
TGTijana Glisic
Tijana Glisic
DPDusan Dj Popovic
Dusan Dj Popovic
ILIva Lolic
Iva Lolic
ATAleksandar Topličanin
Aleksandar Topličanin
KJKatarina Jankovic
Katarina Jankovic
MLMilica Stojkovic Lalosevic
Milica Stojkovic Lalosevic
Background: Liver cirrhosis is the final stage of chronic liver disease. We aimed to evaluate non-invasive scores as predictors of complications and outcome in cirrhotic patients. Methods: A total of 150 cirrhotic patients were included. Models for end-stage liver disease (MELD), albumin-bilirubin (ALBI) score, neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MoLR), and neutrophil-lymphocyte-albumin ratio (NLA) scores were tested in relation to the development of complications and mortality using receiver operating characteristic (ROC) curves. Results: The ROC curve analysis showed (area under the curve) AUC values of NLR, NLA, ALBI, and MELD of 0.711, 0.730, 0.627, and 0.684, respectively, for short-term mortality. MELD, ALBI, and NLA scores showed a statistically significant correlation with hepatic encephalopathy (p = 0.000 vs. 0.014 vs. 0.040, respectively), and the MELD cut-off value of 16 had a sensitivity of 70% and a specificity of 52% (AUC: 0.671, 95% CI (0.577–0.765)). For the assessment of the presence of ascites, the AUC values for NLA and MoLR were 0.583 and 0.658, respectively, with cut-offs of 11.38 and 0.44. Conclusions: MELD, ALBI, and NLA are reliable predictors of hepatic encephalopathy. NLA and MoLR showed a significant correlation with the presence of ascites, and MELD, ALBI, NLR, and NLA have prognostic value to predict 30-day mortality in cirrhotic patients.

4 November 2022 in Life
Verified
Journal Article
Open access
PDF file
ATAleksandar Topličanin
Aleksandar Topličanin
LTLjubisa Toncev
Ljubisa Toncev
VZVera Matovic Zaric
Vera Matovic Zaric
ASAleksandra Sokic-Milutinovic
Aleksandra Sokic-Milutinovic
A wide spectrum of extraintestinal manifestations (EIMs) can burden patients with inflammatory bowel disease (IBD). EIMs contribute fairly to morbidity and mortality rates in IBD patients. Moreover, EIMs in IBD patients are so frequent that some suggest that IBD should be approached as a systemic disorder. Anemia is very common in IBD patients. The two most common types of anemia in IBD, iron deficiency anemia and anemia of chronic disease, are extraintestinal complications. Autoimmune hemolytic anemia (AIHA) is a rare extraintestinal manifestation of IBD, more frequent in ulcerative colitis (UC) than in Crohn’s disease (CD). In this case-based review of the literature, we present a 36-year-old female patient diagnosed with Crohn’s disease (CD) and Coombs positive AIHA, complicated by pulmonary thromboembolism and successfully treated with anti-tumor necrosis factor (anti-TNF) therapy. The underlying pathophysiological mechanism of AIHA in IBD is unclear. Treatment options for AIHA in IBD patients before biologic therapy included corticosteroids alone or in combination with azathioprine (AZA), methotrexate, and surgical treatment (colectomy and/or splenectomy). Currently, biologic therapy is a promising therapeutic option, especially in corticosteroid refractory or corticosteroid-dependent IBD patients with AIHA.

17 January 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
BSBiljana Stankovic
Biljana Stankovic
MSMihajlo Stašuk
Mihajlo Stašuk
VGVladimir Gašić
Vladimir Gašić
BRBojan Ristivojević
Bojan Ristivojević
IGIvana Grubisa
Ivana Grubisa
SPSonja Pavlovic
Sonja Pavlovic
Background/Objectives: Vedolizumab (VDZ), a monoclonal antibody targeting α4β7 integrin, is used in Crohn’s disease (CD) management, yet patients’ responses vary, underscoring the need for pharmacogenomic (PGx) markers. This study aimed to identify PGx pathways associated with suboptimal VDZ response using a rare-variant analytical framework. Methods: DNA from 63 CD patients treated with VDZ as first-line advanced therapy underwent whole-exome sequencing. Clinical response at week 14 classified patients as optimal responders (ORs) or suboptimal responders (SRs). Sequencing data were processed using GATK Best Practices, annotated with variant effect predictors, and filtered for rare damaging variants (damaging missense and high-confidence loss-of-function; minor allele frequency < 0.05). Variants were mapped to genes specific for SRs and ORs, and analyzed for pathway enrichment using the Reactome database. Rare-variant burden and composition differences were assessed with Fisher’s exact test and SKAT-O gene-set association analysis. Results: Suboptimal VDZ response was associated with pathways related to membrane transport (ABC-family proteins, ion channels), L1–ankyrin interactions, and bile acid recycling, while optimal response was associated with pathways involving MET signaling. SKAT-O identified lipid metabolism-related pathways as significantly different—SRs harbored variants in pro-inflammatory lipid signaling and immune cell trafficking genes (e.g., PIK3CG, CYP4F2, PLA2R1), whereas ORs carried variants in fatty acid oxidation and detoxification genes (e.g., ACADM, CYP1A1, ALDH3A2, DECR1, MMUT). Conclusions: This study underscores the potential of exome-based rare-variant analysis to stratify CD patients and guide precision medicine approaches. The identified genes and pathways are potential PGx markers for CD patients treated with VDZ.

6 April 2025 in Life
Verified
Journal Article
Open access
PDF file
DJDunja Jaksic
Dunja Jaksic
SVSasa Vuksanovic
Sasa Vuksanovic
ATAleksandar Topličanin
Aleksandar Topličanin
Jelena Spirić MilovančevićJelena Spirić Milovančević
Jelena Spirić Milovančević
GMGorica Maric
Gorica Maric
ASAleksandra Sokic-Milutinovic
Aleksandra Sokic-Milutinovic
Ulcerative colitis (UC) significantly impacts patients’ health-related quality of life (HRQOL). This study aimed to evaluate HRQOL and the factors affecting it, and the prevalence of anxiety, depression and alexythimia in patients with UC. This cross-sectional study included 248 UC patients (21 with proctitis, 63 with left-sided UC and 164 with extensive colitis). Data were collected using standardized self-administered questionnaires [a socio-demographic questionnaire, General Anxiety Disorder-7 (GAD-7), the Patient Health Questionnaire-9 (PHQ-9), the Toronto Alexithymia Scale (TAS-20) and the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)]. Clinical data on remission status, extraintestinal manifestations, comorbidities and the use of advanced therapies were also collected. Hierarchical regression analysis of variables predicting SIBDQ score was done. Clinical and laboratory remission was present in 95.6% of the patients. The prevalences of depression, anxiety and alexithymia were 44.7%, 34.3% and 30.2%, respectively. There were no differences in the PHQ-9, GAD-7 and TAS-20 scores in relation to remission status. The average SIBDQ score was 56.5. The patients in remission reported better SIBDQ scores compared to the symptomatic patients (p = 0.002). The hierarchical regression analysis showed that remission of disease and a higher depression score influenced HRQOL in the UC patients. The prevalence of depression, anxiety and alexithymia in the UC patients was high. Remission of disease and a high depression score were the main factors related to HRQOL.

8 May 2026 in Life
Verified
Journal Article
Open access
PDF file
Jelena Spirić MilovančevićJelena Spirić Milovančević
Jelena Spirić Milovančević
ATAleksandar Topličanin
Aleksandar Topličanin
SVSasa Vuksanovic
Sasa Vuksanovic
SDSrdjan Djuranovic
Srdjan Djuranovic
AMAleksandra Pavlovic Markovic
Aleksandra Pavlovic Markovic
ASAleksandra Sokic-Milutinovic
Aleksandra Sokic-Milutinovic
Sarcopenia in inflammatory bowel disease can significantly influence disease course. Since current assessment focuses mainly on muscle quantity, we aimed to evaluate muscle function in Crohn’s disease (CD) patients and identify those at increased risk of muscle function impairment. This cross-sectional study included 84 patients with CD (76.2% male, mean age 35 ± 11 years) receiving infliximab. Body composition was assessed by bioelectrical impedance analysis, muscle strength by handgrip strength (HGS), and physical performance by gait speed. Half of the cohort demonstrated reduced muscle strength relative to age- and sex-adjusted norms, while none met criteria for confirmed sarcopenia. One third of the patients had low physical performance and only one patient screened positive for sarcopenia. In multivariable linear regression, sex was the strongest independent predictor of HGS (p < 0.001), followed by ileocolonic disease localization, which was independently associated with lower HGS compared to ileal (p = 0.045) and colonic (p = 0.046). Hemoglobin remained an independent predictor of HGS after multivariable adjustment (p = 0.021). Low muscle strength is common in patients with CD treated with infliximab, even in the absence of low muscle mass. Ileocolonic disease localization and lower hemoglobin levels are predictors of low muscle strength, highlighting the importance of early and comprehensive muscle function assessment in this population.